Sotorasib: first targeted approval for KRAS G12C mutated NSCLC

KRAS mutations are represent one of the most frequent oncogene aberrations in patients with lung cancer and has historically been seen as a non-druggable target. Despite this, in May 2021, the first KRAS-targeted treatment was approved by the FDA for locally advanced or metastatic non-small cell lung cancer (NSCLC). Sotorasib is an irreversible KRAS G12C inhibitor that has been granted breakthrough therapy designation based on the findings of the CodeBreaK 100 trial (NCT03600883). Pasi Jänne, MD, PhD, Dana-Farber/Harvard Cancer Center, Boston, MA, talks on the implications of this approval and what it may lead to in the future. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.